Skip to Content
MDPIMDPI
CancersCancers
PDF
  • Reply
  • Open Access

13 February 2023

Reply to Lissing et al. Comment on “Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947”

,
,
,
,
,
,
,
,
…
1
Division of Gastroenterology and Hepatology, University of Utah, Salt Lake City, UT 84112, USA
2
Department of Internal Medicine, Hurley Medical Center, Michigan State University, Flint, MI 48503, USA
3
Division of Gastroenterology & Hepatology, CHI Health Creighton University Medical Center, Omaha, NE 68131, USA
4
Health Science Library, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY 11040, USA
Cancers2023, 15(4), 1187;https://doi.org/10.3390/cancers15041187
This article belongs to the Special Issue Hepatobiliary and Pancreatic Neoplasms: Biomarkers and Targeted Therapy
Version Notes
Order Reprints
We thank Dr. Lissing and colleagues for providing us with these helpful comments [1]. We are appreciative of your expertise and critical review of our work [2]. We have recognized that there were errors and will take the necessary steps to correct them.
After removing the overlapping articles, which in some cases were not very clear to us but following your assertions, we identified 13 articles, of which 3757 patients had porphyria (of any subtype) (Table 1). Overall, from this cohort, we identified 166 patients who developed cancer. We have also clearly laid out different types of porphyria and the number of cancer cases for each of those subtypes as per your recommendations; please see the table below.
Table 1. Characteristics of patients with porphyria.
While disease severity would be interesting to assess, however, this is difficult to extract from these studies. However, we agree that a large cohort study with this information, including age, would be important for future research efforts.
Again, thank you for your comments.

Author Contributions

Conceptualization, D.R. and A.F.; methodology, D.R. and A.F.; validation, A.F.; data curation, D.R., S.S.D., S.C., J.L., J.S. (Jameel Singh), J.S. (Jayanta Samanta) and A.S.; writing—original draft preparation, D.R. and S.S.D.; writing—review and editing, D.R., S.d.N., M.G., F.P., F.C. and A.S.; supervision, D.R., A.F., R.S. and L.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lissing, M.; Vassiliou, D.; Harper, P.; Sardh, E.; Wahlin, S. Comment on Ramai et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947. Cancers 2023, 15, 795. [Google Scholar] [CrossRef]
  2. Ramai, D.; Deliwala, S.S.; Chandan, S.; Lester, J.; Singh, J.; Samanta, J.; di Nunzio, S.; Perversi, F.; Cappellini, F.; Shah, A.; et al. Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review. Cancers 2022, 14, 2947. [Google Scholar] [CrossRef] [PubMed]
  3. Solis, J.A.; Betancor, P.; Campos, R.; De Salamanca, R.E.; Rojo, P.; Marin, I.; Schüller, A. Association of porphyria cutanea tarda and primary liver cancer: Report of ten cases. J. Dermatol. 1982, 9, 131–137. [Google Scholar] [CrossRef] [PubMed]
  4. Salata, H.; Cortés, J.M.; de Salamanca, R.E.; Oliva, H.; Castro, A.; Kusak, E.; Carreño, V.; Hernandez Guío, C. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J. Hepatol. 1985, 1, 477–487. [Google Scholar] [CrossRef] [PubMed]
  5. Siersema, P.D.; ten Kate, F.J.; Mulder, P.G.; Wilson, J.H. Hepatocellular carcinoma in porphyria cutanea tarda: Frequency and factors related to its occurrence. Liver 1992, 12, 56–61. [Google Scholar] [CrossRef] [PubMed]
  6. Kauppinen, R.; Mustajoki, P. Prognosis of acute porphyria: Occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992, 71, 1–13. [Google Scholar] [CrossRef] [PubMed]
  7. Andant, C.; Puy, H.; Bogard, C.; Faivre, J.; Soulé, J.C.; Nordmann, Y.; Deybach, J.C. Hepatocellular carcinoma in patients with acute hepatic porphyria: Frequency of occurrence and related factors. J. Hepatol. 2000, 32, 933–939. [Google Scholar] [CrossRef] [PubMed]
  8. Fracanzani, A.L.; Taioli, E.; Sampietro, M.; Fatta, E.; Bertelli, C.; Fiorelli, G.; Fargion, S. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J. Hepatol. 2001, 35, 498–503. [Google Scholar] [CrossRef] [PubMed]
  9. Gisbert, J.P.; García-Buey, L.; Alonso, A.; Rubio, S.; Hernández, A.; Pajares, J.M.; García-Díez, A.; Moreno-Otero, R. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur. J. Gastroenterol Hepatol. 2004, 16, 689–692. [Google Scholar] [CrossRef] [PubMed]
  10. Cassiman, D.; Vannoote, J.; Roelandts, R.; Libbrecht, L.; Roskams, T.; Van den Oord, J.; Fevery, J.; Garmyn, M.; Nevens, F. Porphyria cutanea tarda and liver disease. A retrospective analysis of 17 cases from a single centre and review of the literature. Acta Gastroenterol Belg. 2008, 71, 237–242. [Google Scholar] [PubMed]
  11. Lang, E.; Schäfer, M.; Schwender, H.; Neumann, N.J.; Frank, J. Occurrence of Malignant Tumours in the Acute Hepatic Porphyrias. JIMD Rep. 2015, 22, 17–22. [Google Scholar] [CrossRef] [PubMed]
  12. Baravelli, C.M.; Sandberg, S.; Aarsand, A.K.; Tollånes, M.C. Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: A nationwide cohort study. Orphanet J. Rare Dis. 2019, 14, 77. [Google Scholar] [CrossRef] [PubMed]
  13. Baravelli, C.M.; Sandberg, S.; Aarsand, A.K.; Nilsen, R.M.; Tollånes, M.C. Acute hepatic porphyria and cancer risk: A nationwide cohort study. J. Intern Med. 2017, 282, 229–240. [Google Scholar] [CrossRef] [PubMed]
  14. Saberi, B.; Naik, H.; Overbey, J.R.; Erwin, A.L.; Anderson, K.E.; Bissell, D.M.; Bonkovsky, H.L.; Phillips, J.D.; Wang, B.; KSingal, A.; et al. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology 2021, 73, 1736–1746. [Google Scholar] [CrossRef] [PubMed]
  15. Lissing, M.; Vassiliou, D.; Floderus, Y.; Harper, P.; Bottai, M.; Kotopouli, M.; Hagström, H.; Sardh, E.; Wahlin, S. Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. J. Intern Med. 2022, 291, 824–836. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
A Simple, Test-Based Method to Control the Overestimation Bias in the Analysis of Potential Prognostic Tumour Markers
Previous
Surgical Outcomes, Long-Term Recurrence Rate, and Resource Utilization in a Prospective Cohort of 165 Patients Treated by Transanal Total Mesorectal Excision for Distal Rectal Cancer
Next